VERA THERAPEUTICS INC
NASDAQ: VERA (Vera Therapeutics, Inc.)
Last update: 2 days ago, 5:16AM31.63
2.74 (9.48%)
| Previous Close | 28.89 |
| Open | 30.78 |
| Volume | 5,849,178 |
| Avg. Volume (3M) | 1,882,539 |
| Market Cap | 2,279,363,328 |
| Price / Book | 5.11 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2026 |
| Diluted EPS (TTM) | -3.00 |
| Total Debt/Equity (MRQ) | 10.18% |
| Current Ratio (MRQ) | 27.68 |
| Operating Cash Flow (TTM) | -155.26 M |
| Levered Free Cash Flow (TTM) | -97.14 M |
| Return on Assets (TTM) | -23.46% |
| Return on Equity (TTM) | -39.49% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Vera Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 3.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 1.25 |
|
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 3.97% |
| % Held by Institutions | 112.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sofinnova Investments, Inc. | 30 Jun 2026 | 2,793,987 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BOMAN NANCY LEE | 32.23 | - | 44,987 | 1,449,931 |
| Aggregate Net Quantity | 44,987 | |||
| Aggregate Net Value ($) | 1,449,931 | |||
| Aggregate Avg. Buy ($) | 32.23 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BOMAN NANCY LEE | Officer | 03 Aug 2026 | Acquired (+) | 44,987 | 32.23 | 1,449,931 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |